Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P921: ARTIFICIAL INTELLIGENCE...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P921: ARTIFICIAL INTELLIGENCE BASED FDG PET/CT RADIOMICS FOR RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA

P921: ARTIFICIAL INTELLIGENCE BASED FDG PET/CT RADIOMICS FOR RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA

Bibliographic Details
Main Authors: Jacob Shreve, Charalampos Charalampous, Rahma Warsame, Josh Pritchett, Prashant Kapoor, Francis Buadi, Jonas Paludo, David Dingli, Mithun Shah, Amie Fonder, Suzanne Hayman, Nelson Leung, Morie Gertz, Robert Kyle, Stephen Broski, Vincent Rajkumar, Shaji Kumar, Moritz Binder
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000970588.15601.1e
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000970588.15601.1e

Similar Items

  • P812: PREDICTING HIGH-RISK DISEASE BIOLOGY USING ARTIFICIAL INTELLIGENCE BASED FDG PET/CT RADIOMICS IN NEWLY DIAGNOSED MULTIPLE MYELOMA
    by: Jacob Shreve, et al.
    Published: (2023-08-01)
  • P885: SOLITARY PLASMACYTOMA: SINGLE INSTITUTION EXPERIENCE AND SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL OUTCOMES
    by: Charalampos Charalampous, et al.
    Published: (2023-08-01)
  • Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
    by: Utkarsh Goel, et al.
    Published: (2024-03-01)
  • Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
    by: Charalampos Charalampous, et al.
    Published: (2023-12-01)
  • Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
    by: Utkarsh Goel, et al.
    Published: (2023-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs